GlassScriptPhysician profile
Jordan Warnsholz
NPI 1649692732
$8,140.39
in general payments reported to CMS, 2019-2025
39 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,222 · 2022: $935 · 2023: $1,738 · 2024: $2,084 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,901 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,901.22 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,613.51 | 2021-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $897.69 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $842.95 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $701.36 | 2021-2025 | |
| Astellas Pharma US INC | $544.73 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $332.98 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Axsome Therapeutics, INC. | $318.43 | 2023-2025 | Auvelity, Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $279.23 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.56 | 2023-2025 | Xifaxan |
| Corium, LLC | $245.70 | 2023-2024 | Azstarys |
| Antares Pharma, INC. | $201.43 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Sunovion Pharmaceuticals INC. | $188.89 | 2021-2022 | |
| Verona Pharma, INC. | $161.35 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $139.24 | 2023-2025 | Jardiance, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $132.27 | 2021-2025 | Nuedexta, Rexulti |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $109.37 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.96 | 2021-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $108.13 | 2024-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $106.36 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $95.45 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $89.71 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $78.94 | 2022-2024 | Yupelri |
| Esperion Therapeutics, INC. | $73.79 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $68.02 | 2021-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Eisai INC. | $61.23 | 2021 | |
| Pfizer INC. | $53.25 | 2025 | |
| Lundbeck LLC | $53.20 | 2021-2025 | Rexulti |
| Amgen INC. | $48.52 | 2021-2023 | Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $40.11 | 2021 | |
| Phathom Pharmaceuticals, INC. | $36.29 | 2024-2025 | Voquezna |
| Viatris Specialty LLC | $21.03 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $20.28 | 2024 | Gemtesa |
| Alkermes, INC. | $20.09 | 2024 | Vivitrol |
| Supernus Pharmaceuticals, INC. | $19.57 | 2021 | Xyosted |
| Neurocrine Biosciences, INC. | $19.24 | 2025 | |
| Radius Health, INC. | $15.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.39 | 2021 | |
| Allergan, INC. | $11.59 | 2021 | |
| Kyowa Kirin, INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Warnsholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.